Microvascularis coronariabetegseg hypertoniaban

Translated title of the contribution: Microvascular coronary artery disease in hypertension

Research output: Contribution to journalArticle

Abstract

The cause of myocardial ischaemia without major coronary artery disease is microvascular coronary artery disease. The pathophysiological basis of microvascular ischaemia is impaired coronary flow reserve (CFR). Microvascular ischaemia is most frequently associated to hypertension. It is a syndrome of typical chest pain, positive ECG or thallium stress test and normal coronary angiogram. The diagnostic technique of choice is the measurement of CFR reduction at iv. dipyridamole or adenosine infusion. Two main mechanisms account for abnormalities of the coronary microcirculation: myocardial and vascular. Myocardial hypertrophy in combination with increased wall stress may contribute to the reduction of CFR. Interstitial fibrosis including perivascular fibrosis was proposed to be another etiologic factor of impaired coronary microcirculation. Hypertensive remodelling of the coronary microcirculation includes the reduction of vascular density and the increase of the wall/lumen ratio of the small intramyocardial vessels. These alterations can be measured in humans using endomyocardial biopsy. The most important functional factor responsible for microvascular coronary artery disease is endothelial dysfunction, assessed by intracoronary acetilcholin infusion. Microvascular coronary artery disease may be associated with hypertensive heart failure. Hypertensive microvascular coronary artery disease can be reversible, therefore the goals of antihypertensive therapy include not only blood pressure control, regression of hypertrophy and prevention of interstitial fibrosis but also the regression of microvascular abnormalities. Such combined effect can be expected from ACE inhibitors, calcium antagonists and moxonidine.

Original languageHungarian
Pages (from-to)620-625
Number of pages6
JournalLege Artis Medicinae
Volume7
Issue number10
Publication statusPublished - 1997

Fingerprint

Coronary Artery Disease
Hypertension
Microcirculation
moxonidine
Fibrosis
Hypertrophy
Blood Vessels
Ischemia
Dipyridamole
Thallium
Chest Pain
Exercise Test
Angiotensin-Converting Enzyme Inhibitors
Adenosine
Antihypertensive Agents
Myocardial Ischemia
Angiography
Electrocardiography
Heart Failure
Blood Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Microvascularis coronariabetegseg hypertoniaban. / Lengyel, M.

In: Lege Artis Medicinae, Vol. 7, No. 10, 1997, p. 620-625.

Research output: Contribution to journalArticle

@article{01bd81996ce44aed87fb3687ae57a489,
title = "Microvascularis coronariabetegseg hypertoniaban",
abstract = "The cause of myocardial ischaemia without major coronary artery disease is microvascular coronary artery disease. The pathophysiological basis of microvascular ischaemia is impaired coronary flow reserve (CFR). Microvascular ischaemia is most frequently associated to hypertension. It is a syndrome of typical chest pain, positive ECG or thallium stress test and normal coronary angiogram. The diagnostic technique of choice is the measurement of CFR reduction at iv. dipyridamole or adenosine infusion. Two main mechanisms account for abnormalities of the coronary microcirculation: myocardial and vascular. Myocardial hypertrophy in combination with increased wall stress may contribute to the reduction of CFR. Interstitial fibrosis including perivascular fibrosis was proposed to be another etiologic factor of impaired coronary microcirculation. Hypertensive remodelling of the coronary microcirculation includes the reduction of vascular density and the increase of the wall/lumen ratio of the small intramyocardial vessels. These alterations can be measured in humans using endomyocardial biopsy. The most important functional factor responsible for microvascular coronary artery disease is endothelial dysfunction, assessed by intracoronary acetilcholin infusion. Microvascular coronary artery disease may be associated with hypertensive heart failure. Hypertensive microvascular coronary artery disease can be reversible, therefore the goals of antihypertensive therapy include not only blood pressure control, regression of hypertrophy and prevention of interstitial fibrosis but also the regression of microvascular abnormalities. Such combined effect can be expected from ACE inhibitors, calcium antagonists and moxonidine.",
keywords = "coronary flow reserve, endothelial dysfunction, hypertension, microsvascular angina",
author = "M. Lengyel",
year = "1997",
language = "Hungarian",
volume = "7",
pages = "620--625",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "10",

}

TY - JOUR

T1 - Microvascularis coronariabetegseg hypertoniaban

AU - Lengyel, M.

PY - 1997

Y1 - 1997

N2 - The cause of myocardial ischaemia without major coronary artery disease is microvascular coronary artery disease. The pathophysiological basis of microvascular ischaemia is impaired coronary flow reserve (CFR). Microvascular ischaemia is most frequently associated to hypertension. It is a syndrome of typical chest pain, positive ECG or thallium stress test and normal coronary angiogram. The diagnostic technique of choice is the measurement of CFR reduction at iv. dipyridamole or adenosine infusion. Two main mechanisms account for abnormalities of the coronary microcirculation: myocardial and vascular. Myocardial hypertrophy in combination with increased wall stress may contribute to the reduction of CFR. Interstitial fibrosis including perivascular fibrosis was proposed to be another etiologic factor of impaired coronary microcirculation. Hypertensive remodelling of the coronary microcirculation includes the reduction of vascular density and the increase of the wall/lumen ratio of the small intramyocardial vessels. These alterations can be measured in humans using endomyocardial biopsy. The most important functional factor responsible for microvascular coronary artery disease is endothelial dysfunction, assessed by intracoronary acetilcholin infusion. Microvascular coronary artery disease may be associated with hypertensive heart failure. Hypertensive microvascular coronary artery disease can be reversible, therefore the goals of antihypertensive therapy include not only blood pressure control, regression of hypertrophy and prevention of interstitial fibrosis but also the regression of microvascular abnormalities. Such combined effect can be expected from ACE inhibitors, calcium antagonists and moxonidine.

AB - The cause of myocardial ischaemia without major coronary artery disease is microvascular coronary artery disease. The pathophysiological basis of microvascular ischaemia is impaired coronary flow reserve (CFR). Microvascular ischaemia is most frequently associated to hypertension. It is a syndrome of typical chest pain, positive ECG or thallium stress test and normal coronary angiogram. The diagnostic technique of choice is the measurement of CFR reduction at iv. dipyridamole or adenosine infusion. Two main mechanisms account for abnormalities of the coronary microcirculation: myocardial and vascular. Myocardial hypertrophy in combination with increased wall stress may contribute to the reduction of CFR. Interstitial fibrosis including perivascular fibrosis was proposed to be another etiologic factor of impaired coronary microcirculation. Hypertensive remodelling of the coronary microcirculation includes the reduction of vascular density and the increase of the wall/lumen ratio of the small intramyocardial vessels. These alterations can be measured in humans using endomyocardial biopsy. The most important functional factor responsible for microvascular coronary artery disease is endothelial dysfunction, assessed by intracoronary acetilcholin infusion. Microvascular coronary artery disease may be associated with hypertensive heart failure. Hypertensive microvascular coronary artery disease can be reversible, therefore the goals of antihypertensive therapy include not only blood pressure control, regression of hypertrophy and prevention of interstitial fibrosis but also the regression of microvascular abnormalities. Such combined effect can be expected from ACE inhibitors, calcium antagonists and moxonidine.

KW - coronary flow reserve

KW - endothelial dysfunction

KW - hypertension

KW - microsvascular angina

UR - http://www.scopus.com/inward/record.url?scp=0030722107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030722107&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030722107

VL - 7

SP - 620

EP - 625

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 10

ER -